Abstract
Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells (PBMCs), stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975; 16(2): 216–229
Kiessling R, Klein E, Pross H, Wigzell H. “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immuno. 1975; 5(2): 117–121
Béziat V, Hilton HG, Norman PJ, Traherne JA. Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer an. T-cell biology. Immunolog. 2017; 150(3): 248–264
Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 2015; 15(4): 243–254
Chester C, Fritsch K, Kohrt HE. Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy. Front Immunol 2015; 6: 601
He Y, Tian Z. NK cell education via nonclassical MHC and non- MHC ligands. Cell Mol Immuno. 2017; 14(4): 321–330
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immuno. 2008; 9(5): 503–510
Liu Y, Zheng J, Liu Y, Wen L, Huang L, Xiang Z, Lam KT, Lv A, Mao H, Lau YL, Tu W. Uncompromised NKcell activation is essential for virus-specifi. CTL activity during acute influenza virus infection. Cell Mol Immuno. 2017; 14: 1–11
Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels wit. CD8+ T cells. Nat Rev Immuno. 2011; 11(10): 645–657
Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy. Front Immunol 2017; 8: 1178
Shissler SC, Bollino DR, Tiper IV, Bates JP, Derakhshandeh R, Webb TJ. Immunotherapeutic strategies targeting natural killer T cell responses in cancer. Immunogenetics 2016; 68(8): 623–638
Davis ZB, Felices M, Verneris MR, Miller JS. Natural killer cell adoptive transfer therapy: exploiting the first line of defense against cancer. Cancer J 2015; 21(6): 486–491
Zhang QF, Yin WW, Xia Y, Yi YY, He QF, Wang X, Ren H, Zhang DZ. Liver-infiltratin. CD11b-CD27–NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immuno. 2017; 14(10): 819–829
Krneta T, Gillgrass A, Chew M, Ashkar AA. The breast tumor microenvironment alters the phenotype and function of natural killer cells. Cell Mol Immunol 2016; 13(5): 628–639
Lim O, Jung MY, Hwang YK, Shin EC. Present and future of allogeneic natural killer cell therapy. Front Immunol 2015; 6: 286
Morvan M, David G, Sébille V, Perrin A, Gagne K, Willem C, Kerdudou N, Denis L, Clémenceau B, Folléa G, Bignon JD, Retière C. Autologous and allogeneic HLA KIR ligand environments and activating KIR control KIR NK-cell functions. Eur J Immuno. 2008; 38(12): 3474–3486
Wang W, Erbe AK, DeSantes KB, Sondel PM. Donor selection for ex vivo-expanded natural killer cells as adoptive cancer immu- notherapy. Future Oncol 2017; 13(12): 1043–1047
Koehl U, Kalberer C, Spanholtz J, Lee DA, Miller JS, Cooley S, Lowdell M, Uharek L, Klingemann H, Curti A, Leung W, Alici E. Advances in clinical NKcell studies: donor selection, manufacturing and quality control. OncoImmunolog. 2016; 5(4): e1115178
Deng X, Terunuma H, Nieda M, Xiao W, Nicol A. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells. Int Immunopharmaco. 2012; 14(4): 593–605
Li X, He C, Liu C, Ma J, Ma P, Cui H, Tao H, Gao B. Expansion of NKcells from PBMCs using immobilized 4-1BBL and interleukin- 21. Int J Oncol 2015; 47(1): 335–342
Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA. Membrane-boun. IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS On. 2012; 7(1): e30264
Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JDJr, Nair BP, Bellamy WT, Epstein J, Barlogie B, van Rhee F. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologic. 2012; 97(9): 1348–1356
Schmidt-Wolf IGH, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994; 87(3): 453–458
Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induce. CD3+CD56+ killer cells. Ann Hemato. 1997; 74(2): 51–56
Granzin M, Wagner J, Köhl U, Cerwenka A, Huppert V, Ullrich E. Shaping of natural killer cell antitumor activity by ex vivo cultivation. Front Immuno. 2017; 8: 458
Chabannon C, Mfarrej B, Guia S, Ugolini S, Devillier R, Blaise D, Vivier E, Calmels B. Manufacturing natural killer cells as medicinal products. Front Immuno. 2016; 7: 504
Bollino D, Webb TJ. Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. Transl Res 2017; 187: 32–43
Song X, Hong SH, Kwon WT, Bailey LM, Basse P, Bartlett DL, Kwon YT, Lee YJ. Secretory trail-armed natural killer cell-based therapy: in vitro and in vivo colorectal peritoneal carcinomatosis xenograft. Mol Cancer Ther 2016; 15(7): 1591–1601
Piscopo NJ, Mueller KP, Das A, Hematti P, Murphy WL, Palecek SP, Capitini CM, Saha K. Bioengineering solutions for manufacturing challenges in CAR T cells. Biotechnol J 2018; 13(2): 1700095
Hartmann J. Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Me. 2017; 9(9): 1183–1197
Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, Gambell P, Westerman DA, Haurat J, Westwood JA, Scott AM, Kravets L, Dickinson M, Trapani JA, Smyth MJ, Darcy PK, Kershaw MH, Prince HM. Persistence and efficacy of second generation CAR T cell against th. LeY antigen in acute myeloid leukemia. Mol The. 2013; 21(11): 2122–2129
Casucci M, Perna SK, Falcone L, Camisa B, Magnani Z, Bernardi M, Crotta A, Tresoldi C, Fleischhauer K, Ponzoni M, Gregori S, Caligaris Cappio F, Ciceri F, Bordignon C, Cignetti A, Bondanza A, Bonini C. Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene. Mol The. 2013; 21(2): 466–475
Leboeuf C, Mailly L, Wu T, Bour G, Durand S, Brignon N, Ferrand C, Borg C, Tiberghien P, Thimme R, Pessaux P, Marescaux J, Baumert TF, Robinet E. In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells. Mol The. 2014; 22(3): 634–644
Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C. Targeting Ewing sarcoma with activated and GD2- specific chimeric antigen receptor-engineered human NKcells induces upregulation of immune-inhibitory HLA-G. OncoImmunolog. 2017; 6(1): e1250050
Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor(CAR)- transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Si. 2018; 39(2): 167–176
Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol 2017; 8: 1597
Bengsch F, Knoblock DM, Liu A, McAllister F, Beatty GL. CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol Immunother 2017; 66(12): 1609–1617
Li Y, Li D, Du M. TIM-3: a crucial regulator of NKcells in pregnancy. Cell Mol Immuno. 2017; 14: 948–950
Felices M, Miller JS. Targeting KIR blockade in multiple myeloma: trouble in checkpoint paradise? Clin Cancer Res 2016; 22(21): 5161–5163
Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016; 17(9): 1025–1036
McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, Mo X, Byrd JC, Muthusamy N, Awan FT. Therapeuti. CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. OncoImmunolog. 2016; 5(10): e1226720
Gallois A, Silva I, Osman I, Bhardwaj N. Reversal of natural killer cell exhaustion by TIM-3 blockade. OncoImmunolog. 2015; 3(12): e946365
Vego H, Sand KL, Høglund RA, Fallang LE, Gundersen G, Holmøy T, Maghazachi AA. Monomethyl fumarate augments NKcell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cell Mol Immuno. 2016; 13(1): 57–64
Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-a2, interleukin(IL)-2. IL-15, IL-21, and IL- 12. Semin Onco. 2015; 42(4): 539–548
Nielsen CM, Wolf AS, Goodier MR, Riley EM. Synergy between common g chain family cytokines an. IL-18 potentiates innate and adaptive pathways of NKcell activation. Front Immuno. 2016; 7: 101
Srivastava S, Pelloso D, Feng H, Voiles L, Lewis D, Haskova Z, Whitacre M, Trulli S, Chen YJ, Toso J, Jonak ZL, Chang HC, Robertson MJ. Effects of interleukin-18 on natural killer cells: costimulation of activation throug. Fc receptors for immunoglobulin. Cancer Immunol Immunothe. 2013; 62(6): 1073–1082
Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, Chen L, Mécheri S, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Degli-Esposti M, Chaput N, Zitvogel L. Cancerinduced immunosuppression: IL-18-elicited immunoablative NKcells. Cancer Re. 2012; 72(11): 2757–2767
Wu D, Wu P, Qiu F, Wei Q, Huang J. Human gdT-cell subsets and their involvement in tumor immunity. Cell Mol Immuno. 2017; 14(3): 245–253
Pittari G, Filippini P, Gentilcore G, Grivel JC, Rutella S. Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies. Front Immuno. 2015; 6: 230
Liu J, Cao X. Cellular and molecular regulation of innate inflammatory responses. Cell Mol Immuno. 2016; 13(6): 711–721
Mittica G, Capellero S, Genta S, Cagnazzo C, Aglietta M, Sangiolo D, Valabrega G. Adoptive immunotherapy against ovarian cancer. J Ovarian Re. 2016; 9(1): 30
Martín-Antonio B, Suñe G, Perez-Amill L, Castella M, Urbano-Ispizua A. Natural killer cells: angels and devils for immunotherapy. Int J Mol Sc. 2017; 18(9): E1868
Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immuno. 2017; 31: 37–54
Veluchamy JP, Kok N, van der Vliet HJ, Verheu HMW, de Gruijl TD, Spanholtz J. The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments. Front Immuno. 2017; 8: 631
Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunothe. 2010; 59(11): 1739–1744
Hofer E, Koehl U. Natural Killer cell-based cancer immunotherapies: from immune evasion to promising targeted cellular therapies. Front Immuno. 2017; 8: 745
Pegram HJ, Haynes NM, Smyth MJ, Kershaw MH, Darcy PK. Characterizing the anti-tumor function of adoptively transferred NKcells in vivo. Cancer Immunol Immunother 2010; 59(8): 1235–1246
Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Me. 2016; 8(357): 357ra123
Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 2014; 26(2): 161–172
Dahlberg CI, Sarhan D, Chrobok M, Duru AD, Alici E. Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity. Front Immuno. 2015; 6: 605
Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immuno. 2013; 10(3): 230–252
Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, Leenders M, Bohme F, Kok N, Trilsbeek C, Paardekooper J, van der Waart AB, Westerweel PE, Snijders TJF, Cornelissen JJ, Bos GMJ, Pruijt HFM, De Graaf AO, van der Reijden B, Jansen JH, van der Meer A, Huls G, Cany J, Preijers F, Blijlevens NMA, Schaap NM. Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NKcells in older acute myeloid leukemia patients. Clin Cancer Re. 2017; 23(15): 4107–4118
Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Onco. 2010; 28(6): 955–959
Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM. Successful transfer of alloreactive haploidentical KIR ligandmismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Bloo. 2011; 118(12): 3273–3279
Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, Sprague KA, Miller KB, Comenzo RL, Kewalramani T, Yu N. Van Etten RA, McKenna DH. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cellenriched infusions. Transfusio. 2013; 53(2): 412–418, quiz 411
Kottaridis PD, North J, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S, Grace S, Lowdell MW. Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase I trial. PLoS One 2015; 10(6): e0123416
Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved usin. IL-2 diphtheria toxin fusion protein. Bloo. 2014; 123(25): 3855–3863
Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, Gulbis A, Ahmed S, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NKcells after haploidentical transplantation. Blood 2017; 130(16): 1857–1868
Choi I, Yoon SR, Park SY, Kim H, Jung SJ, Jang YJ, Kang M, Yeom YI, Lee JL, Kim DY, Lee YS, Kang YA, Jeon M, Seol M, Lee JH, Lee JH, Kim HJ, Yun SC, Lee KH. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant 2014; 20(5): 696–704
Killig M, Friedrichs B, Meisig J, Gentilini C, Blüthgen N, Loddenkemper C, Labopin M, Basara N, Pfrepper C, Niederwieser DW, Uharek L, Romagnani C. Tracking in vivo dynamics of NKcells transferred in patients undergoing stem cell transplantation. Eur J Immuno. 2014; 44(9): 2822–2834
Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 2017; 177(3): 457–466
Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kühne T, Favre G, Gratwohl A. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemi. 2004; 18(11): 1835–1838
Yoon SR, Lee YS, Yang SH, Ahn KH, Lee JH, Lee JH, Kim DY, Kang YA, Jeon M, Seol M, Ryu SG, Chung JW, Choi I, Lee KH. Generation of donor natural killer cells fro. CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplan. 2010; 45(6): 1038–1046
Rizzieri DA, Storms R, Chen DF, Long G, Yang Y, Nikcevich DA, Gasparetto C, Horwitz M, Chute J, Sullivan K, Hennig T, Misra D, Apple C, Baker M, Morris A, Green PG, Hasselblad V, Chao NJ. Natural killer cell-enriched donor lymphocyte infusions from A 3- 6/. HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplan. 2010; 16(8): 1107–1114
Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG. Cytokineinduced killer(CIK) cells in cancer immunotherapy: report of the international registry o. CIK cells(IRCC). J Cancer Res Clin Onco. 2015; 141(5): 839–849
Hölsken O, Miller M, Cerwenka A. Exploiting natural killer cells for therapy of melanoma. J Dtsch Dermatol Ge. 2015; 13(1): 23–29
Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, Berdel J, Niessner H, Meier F, van den Broek M, Häring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, Zender L, Schaller M, Schulze-Osthoff K, Röcken M. T-helper-1-cell cytokines drive cancer into senescence. Natur. 2013; 494(7437): 361–365
Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. A phase IIstudy of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13(1): 98–107
Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010; 59(12): 1781–1789
Yang Y, Lim O, Kim TM, Ahn YO, Choi H, Chung H, Min B, Her JH, Cho SY, Keam B, Lee SH, Kim DW, Hwang YK, Heo DS. Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. Cancer Immunol Res 2016; 4(3): 215–224
Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherap. 2013; 15(12): 1563–1570
Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NKcells in patients with cancer. Blood 2005; 105(8): 3051–3057
Sadozai H, Gruber T, Hunger RE, Schenk M. Recent successes and future directions in immunotherapy of cutaneous melanoma. Front Immuno. 2017; 8: 1617
Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, Delgoffe GM, Bruno TC, Workman CJ, Vignal DAA. Interferon-g drives Treg fragility to promote anti-tumor immunity. Cel. 2017; 169(6): 1130–1141. e11
Tallerico R, Garofalo C, Carbone E. A new biological feature of natural killer cells: the recognition of solid tumor-derived cancer stem cells. Front Immuno. 2016; 7: 179
Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N. Natural killer cells: role in local tumor growth and metastasis. Biologic. 2012; 6: 73–82
Krasnova Y, Putz EM, Smyth MJ, Souza-Fonseca-Guimaraes F. Bench to bedside: NK cells and control of metastasis. Clin Immuno. 2017; 177: 50–59
Ames E, Canter RJ, Grossenbacher SK, Mac S, Smith RC, Monjazeb AM, Chen M, Murphy WJ. Enhanced targeting of stemlike solid tumor cells with radiation and natural killer cells. OncoImmunology 2015; 4(9): e1036212
Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, Günther C, Gunther S, Habl G, Hautmann H, Hautmann M, Huber RM, Molls M, Offner R, Rödel C, Rödel F, Schütz M, Combs SE, Multhoff G. Heat shock protein 70(Hsp70) peptide activated natural killer(NK) cells for the treatment of patients with non-small cell lung cancer(NSCLC) after radiochemotherapy(RCTx)—from preclinical studies to a clinical phase IItrial. Front Immuno. 2015; 6: 162
Suck G, Linn YC, Tonn T. Natural killer cells for therapy of leukemia. Transfus Med Hemothe. 2016; 43(2): 89–95
Li L, Li W, Wang C, Yan X, Wang Y, Niu C, Zhang X, Li M, Tian H, Yao C, Jin H, Han F, Xu D, Han W, Li D, Cui J. Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma. Cytotherap. 2018; 20(1): 134–148
Fine JH, Chen P, Mesci A, Allan DSJ, Gasser S, Raulet DH, Carlyle JR. Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missingself recognition. Cancer Re. 2010; 70(18): 7102–7113
Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23(10): 2346–2357
Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo AS, Furman WL. A pilot trial of humanized anti-GD2 monoclonal antibody(hu14. 18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma. Clin Cancer Res 2017; 23(21): 6441–6449
Benson DMJr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS. A phase 1 trial of the anti-KIR antibod. IPH2101 in patients with relapsed/refractory multiple myeloma. Bloo. 2012; 120(22): 4324–4333
Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I. Agonists of costimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Onco. 2015; 42(4): 640–655
Anderson AC, Joller N, Kuchroo VK. Lag-3. Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunit. 2016; 44(5): 989–1004
Vallera DA, Felice M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS. IL1. Trispecific killer engagers(TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Re. 2016; 22(14): 3440–3450
Chen S, Li J, Li Q, Wang Z. Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunothe. 2016; 12(10): 2491–2500
Liu D, Tian S, Zhang K, Xiong W, Lubaki NM, Chen Z, Han W. Chimeric antigen receptor(CAR)-modified natural killer cellbased immunotherapy and immunological synapse formation in cancer and HIV. Protein Cel. 2017; 8(12): 861–877
Carlsten M, Childs RW. Genetic manipulation of NKcells for cancer immunotherapy: techniques and clinical implications. Front Immunol 2015; 6: 266
Sutlu T, Nyström S, Gilljam M, Stellan B, Applequist SE, Alici E. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum Gene The. 2012; 23(10): 1090–1100
Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL. Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy 2017; 19(10): 1225–1232
Ayello J, Hochberg J, Flower A, Chu Y, Baxi LV, Quish W, van de Ven C, Cairo MS. Genetically re-engineere. K562 cells significantly expand and functionally activate cord blood natural killer cells: potential for adoptive cellular immunotherapy. Exp Hemato. 2017; 46: 38–47
Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013; 8(10): e76781
Cany J, van der Waart AB, Tordoir M, Franssen GM, Hangalapura BN, de Vries J, Boerman O, Schaap N, van der Voort R, Spanholtz J, Dolstra H. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrowresiding human leukemia cells in NOD/SCID/IL2Rg(null) mice. PLoS On. 2013; 8(6): e64384
Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJN, Lee DA, Kaufman DS. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Me. 2013; 2(4): 274–283
Hermanson DL, Bendzick L, Pribyl L, McCullar V, Vogel RI, Miller JS, Geller MA, Kaufman DS. Induced pluripotent stem cellderived natural killer cells for treatment of ovarian cancer. Stem Cells 2016; 34(1): 93–101
Veluchamy JP, Heeren AM, Spanholtz J, va, Eendenburg JDH, Heideman DAM, Kenter GG, Verheul HM, van der Vliet HJ, Jordanova ES, de Gruijl TD. High-efficiency lysis of cervical cancer by allogeneic NKcells derived from umbilical cord progenitors is independent of HLA status. Cancer Immunol Immunothe. 2017; 66(1): 51–61
Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, Schaap N, Dolstra H. Clinical-grade generation of active NKcells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS On. 2011; 6(6): e20740
Tanaka J, Sugita J, Shiratori S, Shigematu A, Asanuma S, Fujimoto K, Nishio M, Kondo T, Imamura M. Expansion of NKcells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells. Leukemi. 2012; 26(5): 1149–1152
Boerman GH, van Ostaijen-ten Dam MM, Kraal KCJM, Santos SJ, Ball LM, Lankester AC, Schilham MW, Egeler RM, van Tol MJD. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells. Cancer Immunol Immunothe. 2015; 64(5): 573–583
van Ostaijen-ten Dam MM, Prins HJ, Boerman GH, Vervat C, Pende D, Putter H, Lankester A, van Tol MJD, Zwaginga JJ, Schilham MW. Preparation of cytokine-activated NKcells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential. J Immunothe. 2016; 39(2): 90–100
Wendt K, Wilk E, Buyny S, Schmidt RE, Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunolog. 2007; 122(4): 486–495
Koehl U, Sörensen J, Esser R, Zimmermann S, Grüttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D. IL-2 activated NKcell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Di. 2004; 33(3): 261–266
Torelli GF, Rozera C, Santodonato L, Peragine N, D’agostino G, Montefiore E, Napolitano MR, Monque DM, Carlei D, Mariglia P, Pauselli S, Gozzer M, Bafti MS, Girelli G, Guarini A, Belardelli F, Foà R. A good manufacturing practice method to ex vivo expand natural killer cells for clinical use. Blood Transfu. 2015; 13(3): 464–471
Granzin M, Stojanovic A, Miller M, Childs R, Huppert V, Cerwenka A. Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NKcells with therapeutic activity in a xenograft mouse model of melanoma. OncoImmunolog. 2016; 5(9): e1219007
Kim EK, Ahn YO, Kim S, Kim TM, Keam B, Heo DS. Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers. Cytotherapy 2013; 15(2): 231–241. e1
Zhang H, Cui Y, Voong N, Sabatino M, Stroncek DF, Morisot S, Civin CI, Wayne AS, Levine BL, Mackall CL. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunothe. 2011; 34(2): 187–195
Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Progra. 2013; 2013: 234–246
Oyer JL, Igarashi RY, Kulikowski AR, Colosimo DA, Solh MM, Zakari A, Khaled YA, Altomare DA, Copik AJ. Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach. Biol Blood Marrow Transplant 2015; 21(4): 632–639
Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno M, Sakai F, Kato A, Tanabe M, Enoki T, Mineno J, Naito Y, Itoh Y, Yoshikawa T. Phase I clinical trial of autologous NKcell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med 2015; 13(1): 277
Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012; 14(9): 1131–1143
Williams BA, Law AD, Routy B, de Hollander N, Gupta V, Wang XH, Chaboureau A, Viswanathan S, Keating A. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarge. 2017; 8(51): 89256–89268
Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherap. 2008; 10(6): 625–632
Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 2017; 177(3): 457–466
Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011; 17(19): 6287–6297
Liang S, Xu K, Niu L, Wang X, Liang Y, Zhang M, Chen J, Lin M. Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer. Onco Targets The. 2017; 10: 4273–4281
Leivas A, Perez-Martinez A, Blanchard MJ, Martín-Clavero E, Fernández L, Lahuerta JJ, Martinez-Lopez J. Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. OncoImmunolog. 2016; 5(12): e1250051
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivoexpanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunothe. 2015; 38(1): 24–36
Pérez-Martínez A, Fernández L, Valentín J, Martínez-Romera I, Corral MD, Ramírez M, Abad L, Santamaría S, González-Vicent M, Sirvent S, Sevilla J, Vicario JL, de Prada I, Diaz MA. A phase I/ II trial of interleukin-15—stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherap. 2015; 17(11): 1594–1603
Shaffer BC, Le Luduec JB, Forlenza C, Jakubowski AA, Perales MA, Young JW, Hsu KC. Phase IIstudy of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016; 22(4): 705–709
Acknowledgements
This work was supported by the National Natural Science Foundation of China (Nos. 81788101, 91542000, 81671558, and 31571440); the Ministry of Science and Technology of China (No. 2016YFC1303503) and Chinese Academy of Sciences (Nos. XDA12020312, XDPB030301, and XDPB030303).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://doi.org/creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the appropriate credit is given to the original author(s) and the source, and a link is provided to the Creative Commons license, which indicates if changes are made.
About this article
Cite this article
Fang, F., Xiao, W. & Tian, Z. Challenges of NK cell-based immunotherapy in the new era. Front. Med. 12, 440–450 (2018). https://doi.org/10.1007/s11684-018-0653-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11684-018-0653-9